FRAMINGHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today introduced its Atlas Dataset, which provides the foundation for the company’s healthcare commercial intelligence and powers Definitive Healthcare’s existing products, analytics, and solutions. The Atlas Dataset ranked first or second in each of the top ten use cases for healthcare reference and affiliation data, according to an independent third-party research survey conducted in November 2022.
“Over the last decade, we’ve been recognized as a leader in reference and affiliations data, helping clients gain unique intelligence on healthcare entities. We’re excited to package up all the data that our clients know and love in the Atlas Dataset,” said Robert Musslewhite, CEO of Definitive Healthcare. “With the Atlas Dataset, we’re empowering customers to make strategic data-driven decisions based on up-to-date intelligence on the complex and broad healthcare ecosystem.”
Combining multiple datasets on more than 15 million healthcare experts and professionals and 300,000 healthcare organizations, the Atlas Dataset has multiple components, including:
Powering the entire Atlas Dataset is the Definitive ID, a unique identifier assigned to every healthcare individual and organization that provides users with a standard way to navigate the healthcare ecosystem.
By combining multiple datasets under one umbrella, the Atlas Dataset enables clients to better understand the healthcare industry by providing them with deeper context as they identify and engage the right markets, channels, and players. For example, one client used the Atlas Dataset to realize that they had overestimated a potential market for their product by nearly 10x because they had previously only looked at claims data. Another client realized that it had been sending its pharmaceutical sales reps to central billing offices instead of the doctor’s physical offices because it previously lacked the ability to integrate affiliation data, address data, and claims data.
According to the independent research survey, data accuracy and completeness are the key factors that both providers and life sciences companies consider when seeking our reference and affiliations data.
“Even for those of us who have worked in the healthcare space for years, it can be hard to understand the complex relationship between different healthcare organizations,” said Emil Mladenov, vice president of marketing at Inspirata. “We like that the team at Definitive Healthcare has built out a sophisticated relational structure with its affiliation dataset over the years on IDNs, hospitals, and healthcare professionals – and that each entity has a unique identifier – as it allows us to understand the interconnectivity between organizations.”
The Atlas Dataset uses advanced data collection methods to ensure accurate, robust data on entities across the healthcare ecosystem. By leveraging proprietary algorithms, technology such as natural language processing and artificial intelligence, sophisticated data science, as well as manual research and quality checks, Definitive Healthcare can both link intelligence to the Definitive ID as well as create new data elements, helping clients make data-driven strategic decisions.
To learn more about the Atlas Dataset, visit https://www.definitivehc.com/atlas-dataset
About Definitive Healthcare
At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.
Media Contacts:
Danielle Johns
This email address is being protected from spambots. You need JavaScript enabled to view it.
Highwire PR:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Brian Denyeau
ICR for Definitive Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
646-277-1251
Last Trade: | US$2.53 |
Daily Change: | 0.03 1.20 |
Daily Volume: | 535,642 |
Market Cap: | US$292.270M |
February 27, 2025 February 25, 2025 November 07, 2024 October 10, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load